Q-omics provides the consensus-scored TDRD10 profile across patient tissues and cancer cell-line models. TDRD10 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, TDRD10 is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, TDRD10 RNA expression shows 16,382 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LUAD, COAD, and LSCC as cancer lineages where TDRD10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TDRD10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TDRD10 survival associations across molecular data types. TDRD10 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TDRD10 RNA expression–survival associations across cancer types. High TDRD10 expression shows favorable associations in LUAD, UVM, PAAD, UCS, THYM and THCA. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for TDRD10 RNA expression.
This table summarizes TDRD10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for TDRD10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TDRD10 shows lower tumor expression in COAD, BLCA, LUSC, LUAD, UCEC and BRCA. The COAD box plot shows higher TDRD10 RNA expression in normal versus tumor tissue (log2 FC = −0.555, t-test p < 0.001).
This table shows molecular features associated with TDRD10 in patient tissues and cancer cell lines. In patient samples, TDRD10 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, TDRD10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and OESOPHAGUS.
